Indictment of the microglia as the villain in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Over the past decade, considerable attention has focused on the theory that MS is an autoimmune disease mediated by T cells specific for neural autoantigens. [1,2] Infectious agents may play a role in triggering an autoimmune process in a susceptible individual. [3,4] If so, this would reconcile the roles of environmental and genetic factors in the development of MS. The existence of structural similarities between viral antigens and autoantigens (viral mimicry) and the possibility that viral products (super antigens) can amplify T-cell populations have suggested mechanisms by which an infectious agent such as a virus can initiate an autoimmune process. [5,6] An essential element of both hypotheses (molecular mimicry and superantigens) is the expansion and targeting of autoreactive CD4+ T cells to the CNS. Hence, understanding T-cell receptor (TCR) gene usage of autoreactive T cells and their cytokine secretion profile has been a central focus of interest. We propose a model of CNS demyelination that is not predicated upon the continued presence of autoreactive T cells. Instead, we suggest that microglial activation is a central element in CNS demyelination and that the oligodendrocyte-myelin unit is the target. Understanding the nature of microglial activation is likely to offer therapeutic insights to the treatment of MS.
In contrast to autoantibody-mediated autoimmune disease, evidence for the role of autoreactive T cells in autoimmune disease has been difficult to prove. This is in part because T-cell reactivity to autoantigens is present in the normal healthy population and there is no system to test the pathogenicity of autoreactive T cells. Nonetheless, rheumatoid arthritis, MS, inflammatory bowel disease, and insulin-dependent diabetes mellitus are thought to represent T-cell-mediated autoimmune disease. In this paradigm, the end-organ damage is not the result of antibodies to self-antigens but due in part to a delayed type hypersensitivity, cytokines, and cytotoxic T-cell …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Association of Neurofilament Light With the Development and Severity of Parkinson Disease
Dr. Rodolfo Savica and Dr. Parichita Choudhury
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosisSuhayl Dhib-Jalbut et al.Neurology, June 04, 2007 -
Articles
Inflammatory, immune, and viral aspects of inclusion-body myositisMarinos C. Dalakas et al.Neurology, December 16, 2005 -
Articles
Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotypeB. Hemmer, M. Vergelli, L. Tranquill et al.Neurology, October 01, 1997 -
Cytokine Networks in Multiple Sclerosis
Circulating adhesion molecules and inflammatory mediators in demyelinationA reviewHans-Peter Hartung, Juan J. Archelos, Jurgen Zielasek et al.Neurology, June 01, 1995